Kentucky's $42 million allocation for psychedelics research for opioid addiction

31 May 2023

Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion of the Opioid Settlement Funds and use it for psychedelic research, specifically ibogaine for opioid addiction.

AG Cameron will be joined with LrGen Martin Steele and his 501c3 organization  Reason for Hope, who was  instrumental in educating Kentucky lawmakers on the policy and reform necessary to advance access to psychedelic-assisted therapy.

Ibogaine is a naturally occurring psychoactive found in the iboga plant well known for its hallucinogenic powers and a promising treatment for addictions including opioids.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology